(NASDAQ: GMAB) Genmab A's forecast annual revenue growth rate of 11.41% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 101.22%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.31%.
Genmab A's revenue in 2025 is $3,563,740,000.On average, 25 Wall Street analysts forecast GMAB's revenue for 2025 to be $239,553,888,119, with the lowest GMAB revenue forecast at $223,181,269,124, and the highest GMAB revenue forecast at $253,615,078,550. On average, 25 Wall Street analysts forecast GMAB's revenue for 2026 to be $279,490,237,197, with the lowest GMAB revenue forecast at $245,589,284,925, and the highest GMAB revenue forecast at $305,429,602,193.
In 2027, GMAB is forecast to generate $315,702,618,033 in revenue, with the lowest revenue forecast at $276,023,094,351 and the highest revenue forecast at $348,768,887,768.